Stock Events

Stock Events

Jasper Therapeutics 

$0.7086
48
+$0.02+3.23% 20:00 Today
-$0.00-0.56%21:14After hours

Statistics

Day High
0.71
Day Low
0.6642
52W High
2.78
52W Low
0.315
Volume
432,790
Avg. Volume
1,435,261
Mkt Cap
23.58M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.74
-1.17
-0.61
-0.04
Expected EPS
-0.08
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-75.8MNet Income

Analyst Ratings

3.38Average Price Target
The highest estimate is 7.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
40%
Hold
60%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow JSPR. It's not an investment recommendation.
Intel
9
INTC
NVIDIA
8
NVDA
Palantir Technologies
8
PLTR
Microsoft
7
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the innovative therapy space including treatments for cancer and genetic diseases, similar to Jasper's focus on hematologic cancers and gene therapies.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR T cell therapies, a direct competitor to Jasper's work in hematologic malignancies and cell therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space for cancer, overlapping with Jasper's focus areas.
Novartis
NVS
Mkt Cap292.35B
Novartis is a major player in gene and cell therapy, including Kymriah for cancer treatment, competing in the same therapeutic areas as Jasper.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on gene therapy for genetic diseases, competing with Jasper in the broader gene therapy market.
Adaptive Biotechnologies
ADPT
Mkt Cap4.02B
Adaptive Biotechnologies is involved in immune-driven medicine, including cancer, which competes with Jasper's focus on hematologic malignancies and immune therapies.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is developing programmed cellular immunotherapies for cancer and immune disorders, directly competing with Jasper's cell therapy approaches.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is involved in various therapeutic areas including oncology and gene therapy, making it a competitor in the broader market that Jasper operates in.

About

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Show more...
CEO
Jeetinder Singh Mahal
Employees
22
Country
United States
ISIN
US4718712023

Listings

XNAS
US
JSPRW
XNAS
US
JSPR
BOATS
BOATS
JSPR.BOATS

0 Comments

Share your thoughts

FAQ

What is Jasper Therapeutics stock price today?▼
The current price of JSPR is $0.71 USD — it has increased by +3.23% in the past 24 hours. Watch Jasper Therapeutics stock price performance more closely on the chart.
What is Jasper Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Jasper Therapeutics stocks are traded under the ticker JSPR.
Is Jasper Therapeutics stock price growing?▼
JSPR stock has risen by +1.27% compared to the previous week, the month change is a +6.48% rise, over the last year Jasper Therapeutics has showed a -73.66% decrease.
What is Jasper Therapeutics market cap?▼
Today Jasper Therapeutics has the market capitalization of 23.58M
When is the next Jasper Therapeutics earnings date?▼
Jasper Therapeutics is going to release the next earnings report on November 05, 2026.
What were Jasper Therapeutics earnings last quarter?▼
JSPR earnings for the last quarter are -0.1 USD per share, whereas the estimation was -0.27 USD resulting in a +62.66% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Jasper Therapeutics revenue for the last year?▼
Jasper Therapeutics revenue for the last year amounts to 0 USD.
What is Jasper Therapeutics net income for the last year?▼
JSPR net income for the last year is -75.8M USD.
How many employees does Jasper Therapeutics have?▼
As of September 04, 2026, the company has 22 employees.
In which sector is Jasper Therapeutics located?▼
Jasper Therapeutics operates in the Health & Wellness sector.
When did Jasper Therapeutics complete a stock split?▼
The last stock split for Jasper Therapeutics was on January 04, 2024 with a ratio of 1:10.
Where is Jasper Therapeutics headquartered?▼
Jasper Therapeutics is headquartered in REDWOOD CITY, United States.